- Trials with a EudraCT protocol (53)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
53 result(s) found for: Biological pathway.
Displaying page 1 of 3.
| EudraCT Number: 2020-005156-38 | Sponsor Protocol Number: ARISE-ARMYDA7trial | Start Date*: 2021-04-21 |
| Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITà DI NOVARA | ||
| Full Title: AlteRnative antIthrombotic pathwayS in acutE myocardial infarction: a randomized pilot trial | ||
| Medical condition: acute ST-segment elevation myocardial infarction (STEMI) with large coronary thrombus burden (LCTB). | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: IT (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2012-005019-14 | Sponsor Protocol Number: 12076 | Start Date*: 2013-05-03 | |||||||||||
| Sponsor Name:University of Nottingham | |||||||||||||
| Full Title: The short term effects of an AKT inhibitor (AZD5363) on biomarkers of the AKT pathway and anti-tumour activity in a breast cancer paired biopsy study (STAKT Trial) | |||||||||||||
| Medical condition: primary breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-002752-50 | Sponsor Protocol Number: IC2014-10 | Start Date*: 2014-12-05 | |||||||||||
| Sponsor Name:INSTITUT CURIE | |||||||||||||
| Full Title: Phase II clinical trial evaluating the efficacy of the dual inhibition of PIK/Akt/mTor signaling pathway by PF-05212384 (PKI-587) for patients with myeloid neoplasm secondary to chemo-radiotherapy ... | |||||||||||||
| Medical condition: Myeloid neoplasm secondary to chemo-radiotherapy (t-AML/MDS) /or relapsed or refractory de novo AML /or de novo AML at diagnostic considered unfit to benefit from induction therapy with chemotherap... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-001031-22 | Sponsor Protocol Number: CCR2749 | Start Date*: 2007-12-18 |
| Sponsor Name:Institute of Cancer Research | ||
| Full Title: The Potentiation of Efficacy of Radiotherapy in Non-Small-Cell Lung Cancer (NSCLC) by Inhibition of Akt Activation | ||
| Medical condition: Non-small-cell lung cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-003168-22 | Sponsor Protocol Number: 2020/0206/HP | Start Date*: 2021-09-02 | |||||||||||
| Sponsor Name:Rouen University Hospital | |||||||||||||
| Full Title: Multicenter, uncontrolled pilot study evaluating the efficacy of eculizumab in the treatment of gemcitabine-induced thrombotic microangiopathies. | |||||||||||||
| Medical condition: Thrombotic microangiopathies induced by gemcitabine | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-005193-11 | Sponsor Protocol Number: METAL | Start Date*: 2015-03-31 | |||||||||||
| Sponsor Name:King's College London [...] | |||||||||||||
| Full Title: METformin And Longevity (METAL): A window of opportunity study investigating biological effects of metformin in localised prostate cancer | |||||||||||||
| Medical condition: Prostate cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-000519-18 | Sponsor Protocol Number: P160906J | Start Date*: 2019-04-09 | |||||||||||
| Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
| Full Title: PIMOC : Personalized targeted therapies in inflammatory complex multi organ disease | |||||||||||||
| Medical condition: Patients presenting inflammatory non classified disease targeting at least 2 organs involvement: skin, lymph nodes, hemopoietic system, joints, digestive tract. The disease has been resistant to at... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-012714-49 | Sponsor Protocol Number: CHUBX 2009/04 | Start Date*: 2009-11-24 | |||||||||||
| Sponsor Name:CHU de Bordeaux | |||||||||||||
| Full Title: Pilot study of Lapatinib (Tyverb®) in néoadjuvant treatment for patients with locally bladder carcinoma before cystectomy | |||||||||||||
| Medical condition: Bladder carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-003631-36 | Sponsor Protocol Number: RG_12-124 | Start Date*: 2015-02-10 | |||||||||||
| Sponsor Name:University of Birmingham | |||||||||||||
| Full Title: CALiBRe: Assessment of the Mechanism of Action of idelalisib (CAL-101) in B-cell Receptor Pathway Inhibition in CLL | |||||||||||||
| Medical condition: Chronic lymphocytic leukaemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-005401-28 | Sponsor Protocol Number: AOI2021ME_PICKERING | Start Date*: 2022-01-26 |
| Sponsor Name:University Hospital of Clermont-Ferrand | ||
| Full Title: Effects of the combination of magnesium bisphosphonates versus bisphosphonates alone on bone remodeling: Randomized pilot clinical trial | ||
| Medical condition: postmenopausal osteoporosis | ||
| Disease: | ||
| Population Age: Elderly | Gender: Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-003413-26 | Sponsor Protocol Number: MINDEP | Start Date*: 2015-12-14 | |||||||||||
| Sponsor Name:King's College London [...] | |||||||||||||
| Full Title: Understanding the molecular basis for the use of adjunctive anti-inflammatory treatment in treatment resistant depression: a stratified, randomised, placebo-controlled, experimental medicine study ... | |||||||||||||
| Medical condition: Depression | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-001560-14 | Sponsor Protocol Number: FJD-RA-TOF-60418809 | Start Date*: 2021-08-13 |
| Sponsor Name:FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE | ||
| Full Title: Single-center, open-label, uncontrolled clinical trial to evaluate the association between the expression of the JAK / STAT pathway and the response to tofacitinib in patients with refractory rheum... | ||
| Medical condition: Refractory rheumatoid arthritis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-000720-98 | Sponsor Protocol Number: RXC004/0001 | Start Date*: 2017-06-19 | |||||||||||
| Sponsor Name:Redx Pharma plc | |||||||||||||
| Full Title: A Modular, Multi-Arm, Phase 1/2a, Adaptive Design Study To Evaluate The Safety And Tolerability Of RXC004, Alone And In Combination With Anti-Cancer Treatments, In Patients With Advanced Malignancies | |||||||||||||
| Medical condition: Patients with Advanced Malignancies | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-019983-35 | Sponsor Protocol Number: VPA-CdA | Start Date*: 2010-11-24 | |||||||||||
| Sponsor Name:Cliniques universitaires Saint Luc | |||||||||||||
| Full Title: Phase I-II study of low dose CdA combined with valproic acid (VPA) in previously treated B-cell chronic lymphocytic leukemia (CLL) patients. | |||||||||||||
| Medical condition: •B-CLL, as defined by the NCIWG criteria •Patients must have intermediate or high-risk categories of the modified 3-stage Rai and Binet stagings | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-005978-51 | Sponsor Protocol Number: TED6421 | Start Date*: 2008-08-22 |
| Sponsor Name:sanofi-aventis recherche & développement | ||
| Full Title: Uncontrolled, multicenter, dose finding, safety and pharmacokinetic study of AVE1642, an anti-Insulin-like Growth Factor-1 Receptor (IGF-1R/ CD221) monoclonal antibody, administered as single agent... | ||
| Medical condition: Advanced solid tumors | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-004459-38 | Sponsor Protocol Number: TREACE_2015 | Start Date*: 2016-02-24 | ||||||||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | ||||||||||||||||||
| Full Title: EXPLORATIVE STUDY TO IDENTIFY A SPECIFIC TRANSCRIPTOMIC PROFILE FOR PREDICTING THE MAJOR ADVERSE EFFECTS ASSOCIATED WITH CERTICAN (EVEROLIMUS) IN RENAL TRANSPLANT RECIPIENTS: A PHARMACOGENOMIC APPR... | ||||||||||||||||||
| Medical condition: kidney transplant | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2017-000584-33 | Sponsor Protocol Number: 16154DMcA-AS | Start Date*: 2018-02-23 |
| Sponsor Name:Belfast Health and Social Care Trust | ||
| Full Title: Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) trial: An open label dose escalation phase 1 trial followed by a randomised, double-blind, placebo-controlled ... | ||
| Medical condition: Acute Respiratory Distress Syndrome | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-003752-79 | Sponsor Protocol Number: PIONEER | Start Date*: 2017-05-24 | |||||||||||
| Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge | |||||||||||||
| Full Title: Randomised Phase II clinical trial PIONEER- A Pre-operative wIndOw study of letrozole plus PR agonist (Megestrol Acetate) versus letrozole aloNE in post-menopausal patients with ER-positive breast ... | |||||||||||||
| Medical condition: ER-positive, HER2-negative, invasive primary breast cancer of at least 1 cm size | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-003608-11 | Sponsor Protocol Number: RG_12-125 | Start Date*: 2014-02-20 | |||||||||||
| Sponsor Name:University of Birmingham | |||||||||||||
| Full Title: IciCLLe: Assessment of the Mechanism of Action of Ibrutinib (PCI-32765) in B-cell Receptor Pathway Inhibition in CLL. | |||||||||||||
| Medical condition: Chronic Lymphocytic leukaemia | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-001282-40 | Sponsor Protocol Number: MORAb-004-201-Mel | Start Date*: 2011-09-22 | |||||||||||
| Sponsor Name:Morphotek Inc | |||||||||||||
| Full Title: A Study of the Efficacy and PK/PD Relationship of Monotherapy MORAb-004 in Subjects with Metastatic Melanoma | |||||||||||||
| Medical condition: Metastaic Melanoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.